Dr Jas Sanghera, Co-founder and senior partner, TTP Group; Chairman of TTP Labtech
“Indian initiatives driving growth in translational research and biobanking are complementary to our company ethos”
TTP Labtech, an employee-owned, global leader in the design and development of automated instrumentation and consumables for life science applications, based near Cambridge, UK has been supplying products to the Life Science industry in India for nearly 15 years.
TTP Labtech India is now establishing a strong foothold in the genomic and sample management markets, including biobanking. The company is helping to develop and nurture these markets in India and have already installed several arktic and comPOUND units within the area of biobanking. Dr Jas Sanghera, Co-founder and Chairman of TTP Labtech India got in touch with BioSpectrum to share some of his plans. Edited Excerpts;
Tell us about TTP Labtech India journey so far?
TTP Labtech has been selling products into the Life Science market for 17 years. Over this period, India has seen significant investment into this sector from both private and government sources whilst the global impact of Indian research has been increasing.
In recognition, TTP Labtech opened an office in India, Faridabad (Delhi-NCR) in 2015 providing sales, engineering and application support, complimented by a Pan Indian network of distributors and a satellite office in Bengaluru.
Since 2015, TTP Labtech India has developed a wealth of technical expertise within the structural biology, sample management and biobanking markets. By engaging with select manufacturers in these areas we have been able to supplement our portfolio with complementary, including consumables and software, to offer a comprehensive collection of market leading products. Our aim is to make the customers buying experience seamless through providing a complete solution.
Which of your products are dominating the Life Sciences Industry in India?
The automation of protein crystallography screening has made a significant contribution to the rapid expansion of crystallography-based structural biology. Obtaining crystals of a high enough resolution for X-ray diffraction studies can be a time and cost intensive process, as an extensive number of screening and optimization experiments need to be carried out in order to determine ideal conditions for crystal growth.
Our mosquito protein crystallography liquid handling range has been widely adopted within India, the most popular products being mosquito xtal, mosquito LCP and dragonfly crystal. Interestingly, this correlates with global trends where the former two instruments are considered market leading.
What advantage does India provide for your protein crystallography products?
India has supported crystallography research from the 1930’s, although it was in 1950’s when GN Ramachandran was named as a founding father of structural biology. GN Ramachandran was an Indian physicist best known for his development of the Ramachandran plot for validating protein structures but he was also the first person to propose a triplehelical model for the structure of collagen. Since then, India has gone through turbulent times but has excelled in bioinformatics. Thanks to the generous support from a few individuals, funding from the Department of Science and Technology (DST) and other agencies; crystallographic research is on par with leading research laboratories in the rest of the world. In emerging areas, India has established itself among the top publishing countries.
Our leadership position within this market results from offering a robust portfolio of solutionsbased products, coupled with first rate service and application support.
What are some of the upcoming steps for TTP Labtech in India this year?
With a history of innovation and being at the forefront of new technology introduction, TTP Labtech has become an industry leader within the areas of biobanking and nanolitre liquid handling applications, the latter of which includes; protein crystallography and more recently genomics
(NGS, single cell sequencing and high-throughput transcriptomics).
To showcase our solutions within these applications, we will be participating in a plethora of major global conferences, such as AGBT (Advances in Genome Biology and Technology), where we will be promoting our mosquito range of liquid handlers for miniaturised genomics applications. Here we plan to speak to researchers about miniaturising their
NGS (Next-Generation Sequencing), single cell and transcriptomics workflows.
Within sample management this year, TTP Labtech will proudly install an arktic biobanking system into a leading Indian Institute and a comPOUND into a private company for chemical library storage, both of which will strengthen our foothold in India and help to provide a solid foundation for future growth.
What new scientific areas is TTP Labtech exploring in the coming years for strengthening its foothold in India, and why?
One of the primary reasons for establishing our Indian entity, was to nurture and support the growth of new initiatives in India. Short term within India, we anticipate significant growth opportunities within the application areas mentioned above, however, looking to the future, we observe increased market interest in emerging technologies such as cryo-electron microscopy (CryoEM). To further strengthen our foothold within the structural biology market, we are developing novel solutions that address current sample preparation bottlenecks with the aim of improving CryoEM productivity.
What are the main challenges the Indian Life Sciences Industry is facing today?
India is one of the fastest growing economies in the world, however, historically we have seen a lag in the adoption of new technologies and innovations in India. To truly compete on the global stage, this is something India needs to address.
What more can the existing Indian ecosystem offer the Life Sciences Industry for making it a leader?
Becoming a key global leader within Life Sciences will require significant R&D investment from both the Indian Government and private sectors, in conjunction with polices that support and promote innovation. Several initiatives designed to drive growth through innovation are being implemented within Life Science, including the translational research and biobanking markets. To ensure their success, it is imperative that such initiatives are implemented quickly and backedup by a stable cash-flow.
Why is TTP Labtech committed to supporting growth in the life science research market in India?
Indian initiatives driving growth in translational research and biobanking are complementary to our company ethos. We design and manufacture robust, reliable and easy-to-use solutions for life science research. Enabling life scientists through collaboration, deep application knowledge and leading engineering to accelerate research and make a difference together. Many of our innovations have been born out of the desire to create solutions to existing customer problems; and it’s this ethos that drives TTP Labtech’s R&D efforts. Our strengths come from the trust our customers have with us to develop truly unique, automated technologies to meet their needs.